ELIGARD KIT

Peak

leuprolide acetate

NDASUBCUTANEOUSPOWDER
Approved
Jan 2002
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7

Mechanism of Action

acetate, a gonadotropin releasing hormone (GnRH) agonist, acts as an inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of…

Clinical Trials (5)

NCT05341115Phase 4Completed

A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Started Mar 2023
80 enrolled
Central Precocious Puberty
NCT04914195Phase 3Completed

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Started Jul 2021
NCT03695237Phase 3Completed

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

Started Oct 2018
45 enrolled
Central Precocious Puberty (CPP)
NCT02212197Phase 2Completed

Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer

Started Sep 2014
NCT01746849Phase 2Active Not Recruiting

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Started Dec 2012

Loss of Exclusivity

LOE Date
Dec 22, 2041
192 months away
Patent Expiry
Dec 22, 2041

Patent Records (3)

Patent #ExpiryTypeUse Code
11771841
Dec 22, 2041
SubstanceProduct
11931559
Dec 22, 2041
Substance
12397120
Dec 22, 2041
U-4001